HopeStage
Back to all studies
RecruitingNCT06957808

Diroximel fumarate and glutathione in schizophrenia

About this titleRead the official source — NCT06957808
Medication studyAges 18–65United Kingdom
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
London and 2 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 10, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
30
Sponsor
King's College London
Sponsor type
University
Study type
Drug
Intervention type
Drug
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT06957808
Official title
Show the full official title

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

Recruitment & locations

Currently recruiting

London · Birmingham

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is King's College London, a university.

Does this study involve medication?

Yes. The study involves medication, including Diroximel fumarate (DRF) and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies